Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jan;71(1):34-42.
doi: 10.1136/gutjnl-2020-322339. Epub 2020 Dec 31.

First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial

Maria M E Jongsma  1 , Martine A Aardoom  1 , Martinus A Cozijnsen  1 , Merel van Pieterson  1 , Tim de Meij  2 , Michael Groeneweg  3 , Obbe F Norbruis  4 , Victorien M Wolters  5 , Herbert M van Wering  6 , Iva Hojsak  7   8 , Kaija-Leena Kolho  9   10 , Thalia Hummel  11 , Janneke Stapelbroek  12 , Cathelijne van der Feen  13 , Patrick F van Rheenen  14 , Michiel P van Wijk  2 , Sarah T A Teklenburg-Roord  4 , Marco W J Schreurs  15 , Dimitris Rizopoulos  16 , Michail Doukas  17 , Johanna C Escher  1 , Janneke N Samsom  18 , Lissy de Ridder  19
Affiliations
Randomized Controlled Trial

First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial

Maria M E Jongsma et al. Gut. 2022 Jan.

Abstract

Objective: In newly diagnosed paediatric patients with moderate-to-severe Crohn's disease (CD), infliximab (IFX) is initiated once exclusive enteral nutrition (EEN), corticosteroid and immunomodulator therapies have failed. We aimed to investigate whether starting first-line IFX (FL-IFX) is more effective to achieve and maintain remission than conventional treatment.

Design: In this multicentre open-label randomised controlled trial, untreated patients with a new diagnosis of CD (3-17 years old, weighted Paediatric CD Activity Index score (wPCDAI) >40) were assigned to groups that received five infusions of 5 mg/kg IFX at weeks 0, 2, 6, 14 and 22 (FL-IFX), or EEN or oral prednisolone (1 mg/kg, maximum 40 mg) (conventional). The primary outcome was clinical remission on azathioprine, defined as a wPCDAI <12.5 at week 52, without need for treatment escalation, using intention-to-treat analysis.

Results: 100 patients were included, 50 in the FL-IFX group and 50 in the conventional group. Four patients did not receive treatment as per protocol. At week 10, a higher proportion of patients in the FL-IFX group than in the conventional group achieved clinical (59% vs 34%, respectively, p=0.021) and endoscopic remission (59% vs 17%, respectively, p=0.001). At week 52, the proportion of patients in clinical remission was not significantly different (p=0.421). However, 19/46 (41%) patients in the FL-IFX group were in clinical remission on azathioprine monotherapy without need for treatment escalation vs 7/48 (15%) in the conventional group (p=0.004).

Conclusions: FL-IFX was superior to conventional treatment in achieving short-term clinical and endoscopic remission, and had greater likelihood of maintaining clinical remission at week 52 on azathioprine monotherapy.

Trial registration number: ClinicalTrials.gov Registry (NCT02517684).

Keywords: IBD clinical; inflammatory bowel disease; infliximab; paediatric gastroenterology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: LdR reports grants from ZonMW, ECCO, Crocokids and Pfizer and consultancy fees from Abbvie, during the conduct of the study. MAA received a consultant fee from Abbvie, outside the submitted work. MAC reports grants from ZonMw and Crocokids, and grants and non-financial support from Pfizer during the conduct of the study. IH received a payment/honorarium for lectures from BioGaia, Nutricia, Oktal pharma, Nestle, Biocodex and AbelaPharm. K-LK received consultant fees from Abbvie, Biocodex, Ferring, MSD and Tillotts Pharma, and research grants from the Pediatric Research Foundation (Finland) and the Helsinki University Research Fund, outside the submitted work. TH received a consultant fee from Pfizer, outside the submitted work. JS reports personal fees from Nutricia, outside the submitted work. MPvW reports personal fees from Danone and Laborie, outside the submitted work. STAT-R received a consultant fee from Pfizer, outside the submitted work. JCE received consultant fees from Abbvie and Janssen, as well as research support from MSD and Nutricia.

Figures

Figure 1
Figure 1
Trial design. Illustration of treatment procedures in this trial. EEN, exclusive enteral nutrition; IFX, infliximab.
Figure 2
Figure 2
Trial profile. Flow chart of screened, randomised and treated patients. FL-IFX, first-line infliximab treatment.
Figure 3
Figure 3
Proportion of patients who needed treatment escalation. (A) Kaplan-Meier estimates of the time-to-treatment escalation after start of therapy. Any additional CD-related therapy or surgery during the 52 weeks was considered treatment escalation. Additional CD-related therapy in the FL-IFX group included: (1) any course of corticosteroids, (2) increase of the IFX dose, (3) shortening of the IFX treatment interval, (4) continuation or restart of IFX after the standard five infusions or (5) start of another biological agent. In the conventional treatment group, additional CD-related therapy included start of IFX and any course of corticosteroids that was additional to the standard treatment. (B) Proportion of patients receiving each treatment option from 10 weeks onwards, depicted per randomised group. AZA, azathioprine; CD, Crohn’s disease; CS, corticosteroid; FL-IFX, first-line infliximab.
Figure 4
Figure 4
Proportion of patients in clinical remission without treatment escalation. The proportion of patients in clinical remission, defined as a weighted Paediatric Crohn’s Disease Activity Index <12.5, without treatment escalation at 52 weeks after the start of induction therapy. CS, corticosteroid; EEN, exclusive enteral nutrition; FL-IFX, first-line infliximab.
See this image and copyright information in PMC

Comment in

References

    1. Hyams J, Crandall W, Kugathasan S, et al. . Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863–73. quiz 1165-6. 10.1053/j.gastro.2006.12.003 - DOI - PubMed
    1. Ruemmele FM, Veres G, Kolho KL, et al. . Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014;8:1179–207. 10.1016/j.crohns.2014.04.005 - DOI - PubMed
    1. Borrelli O, Cordischi L, Cirulli M, et al. . Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006;4:744–53. 10.1016/j.cgh.2006.03.010 - DOI - PubMed
    1. Mack DR, Benchimol EI, Critch J, et al. . Canadian association of gastroenterology clinical practice guideline for the medical management of pediatric luminal Crohn's disease. Gastroenterology 2019;157:320–48. 10.1053/j.gastro.2019.03.022 - DOI - PubMed
    1. Lee YM, Kang B, Lee Y, et al. . Infliximab "Top-Down" Strategy is Superior to "Step-Up" in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2015;60:737–43. 10.1097/MPG.0000000000000711 - DOI - PubMed

Publication types

Associated data